Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IPP 204106

Drug Profile

IPP 204106

Alternative Names: IPP-204106; IPP204106N; Nucant programme IPP-204106; polyplexed Nucant; poyplexed IPP-204106

Latest Information Update: 04 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CNRS
  • Developer CNRS; ImmuPharma
  • Class Antineoplastics; Eye disorder therapies; Peptides; Skin disorder therapies
  • Mechanism of Action Nucleolin inhibitors; Nucleophosmin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours
  • No development reported Age-related macular degeneration; Diabetic retinopathy; Psoriasis; Wounds

Most Recent Events

  • 25 Sep 2018 Incanthera signs Heads of Terms on a prospective licensing agreement with ImmuPharma for IPP 204106 for treatment of Cancer
  • 28 Jan 2018 No recent reports of development identified for research development in Age-related-macular-degeneration in France (Parenteral)
  • 16 Jul 2016 No recent reports of development identified for research development in Diabetic-retinopathy in France (Parenteral, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top